Search research articles
Contact Us
Filters
Showing results (321-330 of 419) with videos related to
Page
of 42
Sort By:
Plos One
|
April 1, 2015
Common variation at 1q24.1 (ALDH9A1) is a potential risk factor for renal cancer
Marc Y R Henrion, Mark P Purdue, Ghislaine Scelo, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 27, 2017
Health-related quality of life results from the phase III CheckMate 067 study
Dirk Schadendorf, James Larkin, Jedd Wolchok, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 13, 2023
Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial
Paolo Antonio Ascierto, Evan J Lipson, Reinhard Dummer, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 24, 2018
An open-label, multicentre safety study of vemurafenib in patients with BRAF<sup>V600</sup>-mutant metastatic melanoma: final analysis and a validated prognostic scoring system
James Larkin, Michael P Brown, Ana M Arance, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 6, 2017
Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis
Sandra P D'Angelo, James Larkin, Jeffrey A Sosman, et al.
Nature Ecology & Evolution
|
May 18, 2021
Selection of metastasis competent subclones in the tumour interior
Yue Zhao, Xiao Fu, Jose I Lopez, et al.
Nature Genetics
|
February 4, 2014
Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing
Marco Gerlinger, Stuart Horswell, James Larkin, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 22, 2015
Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma
Dirk Schadendorf, Mayur M Amonkar, Daniil Stroyakovskiy, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 24, 2018
Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study
Sara Valpione, Matteo S Carlino, Johanna Mangana, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 18, 2018
Corrigendum to "Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study*" [Eur J Cancer 91 (2018) 116-124]
Sara Valpione, Matteo S Carlino, Johanna Mangana, et al.
Page
of 42
Search research articles
Search
Showing results (321-330 of 419) with videos related to
Sort By:
Page
of 42
Plos One
|
April 1, 2015
Common variation at 1q24.1 (ALDH9A1) is a potential risk factor for renal cancer
Marc Y R Henrion, Mark P Purdue, Ghislaine Scelo, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 27, 2017
Health-related quality of life results from the phase III CheckMate 067 study
Dirk Schadendorf, James Larkin, Jedd Wolchok, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 13, 2023
Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial
Paolo Antonio Ascierto, Evan J Lipson, Reinhard Dummer, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 24, 2018
An open-label, multicentre safety study of vemurafenib in patients with BRAF<sup>V600</sup>-mutant metastatic melanoma: final analysis and a validated prognostic scoring system
James Larkin, Michael P Brown, Ana M Arance, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 6, 2017
Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis
Sandra P D'Angelo, James Larkin, Jeffrey A Sosman, et al.
Nature Ecology & Evolution
|
May 18, 2021
Selection of metastasis competent subclones in the tumour interior
Yue Zhao, Xiao Fu, Jose I Lopez, et al.
Nature Genetics
|
February 4, 2014
Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing
Marco Gerlinger, Stuart Horswell, James Larkin, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 22, 2015
Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma
Dirk Schadendorf, Mayur M Amonkar, Daniil Stroyakovskiy, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 24, 2018
Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study
Sara Valpione, Matteo S Carlino, Johanna Mangana, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 18, 2018
Corrigendum to "Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study*" [Eur J Cancer 91 (2018) 116-124]
Sara Valpione, Matteo S Carlino, Johanna Mangana, et al.
Page
of 42